pSivida Corp (PSDV) CEO To Discuss Company’s Sustained Release Delivery System For Biologics At Two Upcoming Conferences
4/1/2014 9:06:26 AM
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida’s president and chief executive officer, Dr. Paul Ashton, will discuss pSivida’s Tethadur™ technology designed to provide sustained delivery of biologics at The World Ophthalmology Conference in Tokyo, April 2-6 and at the SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8.
Help employers find you! Check out all the jobs and post your resume.
comments powered by